To date, tens of thousands of patients are benefiting or have been treated with the RGTA®-based therapy which was used to treat a wide range of wound types [1]. RGTA® abilities to heal skin wounds has been proven with patients mostly presenting with chronic ulcers associated with diabetes [2,3], limb ischemia [4], pressure ulcers, vascular-related cutaneous defects [5], burns [6] etc. which could be aggravated when patients undergo renal dialysis or immuno-suppression treatments (cases illustrated to the right). Moreover, RGTA® treatment successfully apply to patients presenting with ulcers caused by radiation [7]  or some rare diseases such as  epidermolysis bullosa [8], sickle-cell disease [9] or  Stewart-Bluefarb syndrome [10]. In addition to chronic wounds, RGTA® were also used for treating acute lesions, such as after trauma or illustrated by cases of patients suffering from open wound trauma or recovering from reconstructive and plastic surgery [11].

Most patients treated with RGTA® are adults, but some successful results were observed with a 10-year-old patient presenting with Charcot’s syndrome, who ran a high risk of leg amputation.

Interestingly, pain relief was reported and measured in several cases by patients treated with RGTA® [4, 5, 8, 9]. Although, the molecular mechanism underlying this phenomenon is yet ill-defined, this observation is of great importance as to the role of RGTA® in injury treatment as well as patients’ quality of life.

Noteworthy, the patients treated with RGTA® have been presented with unsatisfactory treatment solutions as they failed to respond to standard treatment of wound healing and were considered in therapeutic failure. Altogether, these observations show the importance of RGTA® treatment with respect to the health state and the well-being of patients.

CACIPLIQ20® is the RGTA®-based product commercialized by OTR3. It  increases the speed and quality of skin repair by protecting the matrix microenvironment of the wound.




Diabetic foot

Diabetic patient: 56 years old
Type 2 diabetes (17 years)
Hb1Ac : 7%, non-complicated
GNB local infection treated (10 days: ciflox + falgyl)
Plantar wound (6 years)



Diabetic foot

Diabetic patient: 57 years old
Type 2 diabetes
Hb1Ac : 10%
GNB local infection treated (10 days: ciflox + falgyl)
Plantar wound (3 months)



Diabetic foot

Diabetic patient: 48 years old
Type 2 diabetes
HBg : 96g/L
Partial amputation
Presented with critical limb ischemia, gangrenous lateral 4 toes
Started different kinds of local wound care, then started on matrix therapy




Diabetic foot

Diabetic patient: 55 years old
Type 2 diabetes
Post operative wound
Wound < 6 months
Neuropathic foot



Diabetic foot

Diabetic patient:66 years old
Type 2 diabetes
HBg : 11.5 g/l
Wound in the heel region



Chronic kidney disease

Age : 87 years
Chronic kidney disease under dialysis
Leg traumatism with subcutanueous heamatoma and skin necrosis (60 cm2)
Surgical excision and Cacipliq20® (6applications)



Chronic kidney disease

Age: 85 years
Chronic kidney disease, dialysis
Leg damaged by wound with skin loss (60 cm2)
Excision and Cacipliq20® (8 applications)



Post-radiation sarcoma removal

Age : 74 years
Diabetes : Type 2
Diabetes control : Yes
HBg : 10,8g/l
Ulcer site : Left leg distal third
Soft tissue sarcoma
Excised and skin grafted
Radiotherapy given



Post-radiation sarcoma removal

Patient suffering from multiple basal cell carcinomas
Radiation-induced scalp lesions
12-week application of Cacipliq20®



Venous ulcer

Diabetic patient: 60 years old
Type 2 diabetes
Complete healing after a 4-week application of Cacipliq20®



Venous ulcer

Age: 88 years – Non diabetic
Treated with antibiotics, then with Cacipliq20®


Diabetic patient: 64 years old
Type 2 diabetes
Burn with hot wter
Ischaemic , Neuropathic
1.5 Months No Improvement
Using Ag & Anti Microbial dressing
Cacipliq20® application 3 times / week

36 days: Complete Healing


Diabetic patient
Type 2 diabetes
Burn non healing for more than 3-months
Almost complete healing after Cacipliq20® application (4 weeks)


Tendon uncovered



Epidermolysis Bullosa

Age: 12 years
Patient suffering from Epidermolysis Bullosa
Several amputations of the limbs
Treatment with Cacipliq20®
80% pain reduction



Sickle cell ulcer

Age: 25 years
Non-healing sickle cell ulcer
Healing after an 8-week application of Cacipliq20® (2 times/week)



1- Barritault, D., Gilbert-Sirieix, M., Rice, K.L., Siñeriz, F., Papy-Garcia, D., Baudouin, C., Desgranges, P., Zakine, G., Saffar, J.-L., and van Neck, J. (2016). RGTA® or ReGeneraTing Agents mimic heparan sulfate in regenerative medicine: from concept to curing patients. Glycoconjugate Journal. - PDF

2- Slim, I., Tajouri, H., Barritault, D., Njah, M.K, Ach, K., Chaieb, M.C., and Chaieb, L. (2012). Matrix protection therapy in diabetic foot ulcers: pilot study of CACIPLIQ20®. J. Wound Technol. 17 (V), 36–40. - PDF

3- Papanas, N., Demetzos, C., Pippa, N., Maltezos, E., and Tentolouris, N. (2016). Efficacy of a New Heparan Sulfate Mimetic Dressing in the Healing of Foot and Lower Extremity Ulcerations in Type 2 Diabetes: A Case Series. Int J Low Extrem Wounds 15, 63–67. - PDF

4- Desgranges, P., Louissaint, T., and Allaire, E. (2011). First clinical pilot study on critical ischemic leg ulcers with matrix therapy ReGeneraTing agent (RGTA®) technology. J. Wound Technol. 13, 44–8. - PDF

5- Groah, S.L., Libin, A., Spungen, M., Nguyen, K.-L., Woods, E., Nabili, M., Ramella-Roman, J., and Barritault, D. (2011). Regenerating matrix-based therapy for chronic wound healing: a prospective within-subject pilot study. International Wound Journal 8, 85–95. - PDF

6- Barritault, D., Al Harbi, S., Filipe, G.S. (2012) La thérapie matricielle une nouvelle branche de la médecine régénérative et ses applications dans le traitement des brulés: Du fondamental à la clinique. Brulure. 13, 23–7. - PDF

7- Neck, J.W.V., Zuidema, Y.S., Smulders, M., and Balmus, K.J. (20115-6). Unexpected healing of radiation-induced scalp lesions with OTR4120, a heparan sulfate mimetic. European Journal of Dermatology 451–452. - PDF

8- Malaq, A.A., and Denis, B. (2012). A Rapid Response to Matrix Therapy With RGTA in Severe Epidermolysis Bullosa. Eplasty 12, ic15. - PDF

9- Hayek, S., Dibo, S., Baroud, J., Ibrahim, A., and Barritault, D. (2016). Refractory sickle cell leg ulcer: is heparan sulphate a new hope?: Refractory sickle cell leg ulcer: is heparan sulphate a new hope? International Wound Journal 13, 35–38. - PDF

10- Hayek, S., Atiyeh, B., Zgheib, E. (2016) Stewart-Bluefarb syndrome: review of the literature and case report of chronic ulcer treatment with heparan sulphate (Cacipliq20®). Int. Wound J. 12(2), 169–72. - PDF

11- Zakine, G., and Le Louarn, C. (2010). Premières applications de la thérapie matricielle en chirurgie plastique et esthétique. Annales de Chirurgie Plastique Esthétique 55, 421–428. - PDF